Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial
Pharmacology, Toxicology and Pharmaceutical Science
2
2%
Biochemistry, Genetics and Molecular Biology
1
<1%
Other
7
6%
Unknown
66
55%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2023.
All research outputs
#2,845,064
of 27,145,244 outputs
Outputs from Annals of Oncology
#1,670
of 8,561 outputs
Outputs of similar age
#53,172
of 346,330 outputs
Outputs of similar age from Annals of Oncology
#32
of 102 outputs
Altmetric has tracked 27,145,244 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,561 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,330 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
